NVO Novo Nordisk (NVO) Q2 FY25 earnings call
Novo Nordisk delivered strong first-half 2025 results, driven by robust growth in GLP-1 products across both U.S. and International Operations, significantly expanding its patient reach. However, the company revised down its full-year outlook, citing lower growth expectations for Wegovy and Ozempic in the U.S. due to persistent compounding and for Wegovy in some international markets. The strategic focus remains on diabetes and obesity, advancing a promising R&D pipeline, and ensuring commercial execution under new leadership.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
NVO operating KPIs by quarter
| KPI | This call Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Change vs prior quarter |
|---|---|---|---|
| Patients Diabetes and obesity | <46MStarting with our focus on purpose and sustainability, we are now serving almost 46 million patients with our diabetes and obesity treatments.Source: earnings call transcript | ~46MWe're now serving around 46 million people living with diabetes and obesity.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.